#$%^&*AU2019240562A120191017.pdf#####ABSTRACT A pharmaceutical composition for treating an ocular condition, comprising: A) a biodegradable polymer matrix； and B) at least one therapeutic agent homogenously dispersed within the polymer matrix； and wherein the pharmaceutical composition is formulated for intravitreal administration to a subject's eye； and wherein the pharmaceutical composition is formulated to release the therapeutic agent for at least about 4 months.1/57 FIG. IA SDSA25 Dexamethasone Release at 370 C (0.1% Triton X-100) -150 100T 0 0.A 0 28 56 84 112 140 168 196 224 252 280 308 Time (Days) +ENV-1R-0119-7-1 RG502S/RG502H (50/50) ENV-1R-0119-7-5 R203S/RG502S(50150) *ENV-1 R-0119-7-2 RG502S ENV-1 R-0119-7-6 R203S/RG502H(50/50) + ENV-1R-0119-7-3 RG502H ENV-1R-C119-7-7 R203S/R502S(70/30) +ENV-1R-0119-7-4 RG503S/RG502H (50/50)
